239 related articles for article (PubMed ID: 32945223)
1. OX40 agonists for cancer treatment: a patent review.
Cebada J; Perez-Santos M; Bandala C; Lara-Padilla E; Herrera-Camacho I; Rosas-Murrieta NH; Millán-Pérez Peña L; Monjaraz E; Flores A; Anaya-Ruiz M
Expert Opin Ther Pat; 2021 Jan; 31(1):81-90. PubMed ID: 32945223
[TBL] [Abstract][Full Text] [Related]
2. LAG-3 antagonists by cancer treatment: a patent review.
Perez-Santos M; Anaya-Ruiz M; Cebada J; Bandala C; Landeta G; Martínez-Morales P; Villa-Ruano N
Expert Opin Ther Pat; 2019 Aug; 29(8):643-651. PubMed ID: 31291131
[No Abstract] [Full Text] [Related]
3. Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L
Expert Opin Ther Pat; 2019 Jul; 29(7):481-485. PubMed ID: 31216214
[No Abstract] [Full Text] [Related]
4. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L; Rosas-Murrieta NH
Expert Opin Ther Pat; 2019 Dec; 29(12):921-924. PubMed ID: 31627712
[No Abstract] [Full Text] [Related]
5. Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.
Anaya-Ruiz M; Bandala C; Landeta G; Martínez-Morales P; Zumaquero-Rios JL; Sarracent-Pérez J; Pérez-Santos M
Recent Pat Anticancer Drug Discov; 2019; 14(1):85-94. PubMed ID: 30381087
[TBL] [Abstract][Full Text] [Related]
6. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
7. Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association.
Quintella CM; Quintella HM; Rohweder M; Quintella GM
Expert Opin Ther Pat; 2020 Apr; 30(4):287-301. PubMed ID: 32008403
[No Abstract] [Full Text] [Related]
8. Patent trend and competitive analysis of cancer immunotherapy in the United States.
Pan CL; Chen FC
Hum Vaccin Immunother; 2017 Nov; 13(11):2583-2593. PubMed ID: 28881159
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology and Protection of Intellectual Property: Emerging Trends.
Siri JGS; Fernando CAN; De Silva SNT
Recent Pat Nanotechnol; 2020; 14(4):307-327. PubMed ID: 32532198
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors: a patent review (2010-2015).
Collin M
Expert Opin Ther Pat; 2016 May; 26(5):555-64. PubMed ID: 27054314
[TBL] [Abstract][Full Text] [Related]
11. Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.
Satyanarayana K; Srivastava S
Open AIDS J; 2010 Jan; 4():41-53. PubMed ID: 20148091
[TBL] [Abstract][Full Text] [Related]
12. Herbal Technological Prospects of
Alves LP; Dos Santos WM; de Souza ML; Rolim LA; Rolim-Neto PJ
Recent Pat Biotechnol; 2024; 18(3):241-256. PubMed ID: 37605394
[TBL] [Abstract][Full Text] [Related]
13. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
14. An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Wang R; Gao C; Raymond M; Dito G; Kabbabe D; Shao X; Hilt E; Sun Y; Pak I; Gutierrez M; Melero I; Spreafico A; Carvajal RD; Ong M; Olszanski AJ; Milburn C; Thudium K; Yang Z; Feng Y; Fracasso PM; Korman AJ; Aanur P; Huang SA; Quigley M
Clin Cancer Res; 2019 Nov; 25(22):6709-6720. PubMed ID: 31573956
[TBL] [Abstract][Full Text] [Related]
15. Emerging patents in the therapeutic areas of glioma and glioblastoma.
Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.
Redmond WL
Expert Opin Biol Ther; 2023; 23(9):901-912. PubMed ID: 37587644
[TBL] [Abstract][Full Text] [Related]
17. Exploration of Global Trend on Biomedical Application of Polyhydroxyalkanoate (PHA): A Patent Survey.
Paulraj P; Vnootheni N; Chandramohan M; Thevarkattil MJP
Recent Pat Biotechnol; 2018; 12(3):186-199. PubMed ID: 29384069
[TBL] [Abstract][Full Text] [Related]
18. Analysis of anti-asthmatic drug patents published in China between 2004 and 2013.
Xie H; Zhang H; Cao K; He P; Dai H; He S
Expert Opin Ther Pat; 2016; 26(3):363-76. PubMed ID: 26742645
[TBL] [Abstract][Full Text] [Related]
19. The effect of aging on OX40 agonist-mediated cancer immunotherapy.
Ruby CE; Weinberg AD
Cancer Immunol Immunother; 2009 Dec; 58(12):1941-7. PubMed ID: 19288101
[TBL] [Abstract][Full Text] [Related]
20. Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
